Basic HTML Version
Do more than lower blood glucose.
Grab diabetes
by the roots
TM
For people with type 2 diabetes
Novo Nordisk (Pty) Ltd. Reg. No.: 1959/000833/07. 2nd Floor, Building A, 345 Rivonia Boulevard, Edenburg, Rivonia, Sandton 2128, South Africa.
Tel: (011) 202 0500 Fax: (011) 807 7989 www.novonordisk.co.za NN/DUO/5281/January/2012/ver1
References:
1.
Nauck M,
et al;
for the LEAD-2 Study Group. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination with Metformin, in Type 2 Diabetes. The LEAD (Liraglutide Effect and Action
in Diabetes)-2 study.
Diabetes Care.
2009;32(1):84-90.
2.
Gallwitz B, et al. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time.
Int J Clin Pract.
2010;64(2):267-276.
3.
Garber A,
et al;
on behalf of the LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy
compared with glimepiride in patients with type 2 diabetes.
Diabetes, Obes Metab.
2011; 13: 348-356.
4.
Chang AM,
et al.
The GLP-1 Derivative NN2211 Restores ß-cell Sensitivity to Glucose in Type 2 Diabetic Patients
After a Single Dose.
Diabetes.
2003;52:1786-1791.
Proprietary Name:
Victoza
®
.
Scheduling Status:
S4
Composition:
Liraglutide 6 mg/ml.
Indications:
As an adjunct to diet and exercise to achieve glycaemic control in patients with type 2 diabetes mellitus.
Registration Number:
43/21.13/0781. For full prescribing information refer to package insert approved by the medicines regulatory authority.
Victoza
®
is the first and only human
GLP-1 analogue with 97 % homology
to natural GLP-1
Reductions in HbA
1C
1-3
Reductions in weight
1-3
Reductions in systolic blood pressure
1-3
Improvements in beta-cell function
4